The Natriuretic Peptides for Hypertension Treatment.
ANP
ARNi
Hypertension
MANP
NEP inhibitor
Natriuretic peptides
Journal
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
ISSN: 1179-1985
Titre abrégé: High Blood Press Cardiovasc Prev
Pays: New Zealand
ID NLM: 9421087
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
24
09
2021
accepted:
26
10
2021
pubmed:
3
11
2021
medline:
19
1
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Hypertension is a common pathological condition predisposing to a higher occurrence of cardiovascular diseases and events. Unfortunately, treatment of hypertension is still suboptimal worldwide. More efforts are needed to implement the availability of anti-hypertensive drugs. The family of natriuretic peptides, including atrial and brain natriuretic peptides (ANP and BNP), play a key role on blood pressure regulation through the natriuretic, diuretic and vasorelaxant effects. A large number of experimental and human studies, ranging from pathophysiological to genetic investigations, supported ANP as the most relevant component of the family able to modulate blood pressure and to contribute to hypertension development. On this background, it is expected that ANP-based therapeutic approaches may give a significant contribution to the development of efficacious therapies against hypertension. Since native ANP cannot be administered due to its short half-life, several approaches were attempted over the years to overcome the difficulties inherent to the ANP instability. These approaches included ANP recombinant and fusion peptides, gene therapy, inhibition of ANP degradation by neprilysin inhibition, and designer peptides. The most relevant achievements in the field are discussed in this article. Based on the available evidence, therapies targeting ANP represent efficacious and clinically applicable anti-hypertensive agents.
Identifiants
pubmed: 34727352
doi: 10.1007/s40292-021-00483-5
pii: 10.1007/s40292-021-00483-5
doi:
Substances chimiques
Natriuretic Peptides
0
Natriuretic Peptide, Brain
114471-18-0
Atrial Natriuretic Factor
85637-73-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-21Informations de copyright
© 2021. Italian Society of Hypertension.
Références
Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743.
Ives CW, Oparil S. What is the first choice for blood pressure treatment? Lancet. 2019 Nov 16;394(10211):1782–4.
pubmed: 31668725
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group 2018. ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
pubmed: 30165516
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 (S0140-6736(21)01330-1).
Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. JAMA. 2020;324(12):1190–200.
pubmed: 32902588
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89–94.
pubmed: 7219045
de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science. 1985;230(4727):767–70.
pubmed: 2932797
Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698–717.
pubmed: 32444692
Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, Naga Prasad SV, Miller RE, Malfait AM, Zhou Y, Wu Q. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015;21(9):1048–53.
pubmed: 26259032
pmcid: 4710517
Volpe M, Rubattu S. Novel insights into the mechanisms regulating pro-atrial natriuretic peptide cleavage in the heart and blood pressure regulation: proprotein convertase subtilisin/kexin 6 is the corin activating enzyme. Circ Res. 2016;118(2):196–8.
pubmed: 26838312
Meyer M, Richter R, Forssmann WG. Urodilatin, a natriuretic peptide with clinical implications. Eur J Med Res. 1998;3(1–2):103–10.
pubmed: 9512977
Skelton WP 4th, Pi GE, Vesely DL. Four cardiac hormones cause death of human cancer cells but not of healthy cells. Anticancer Res. 2011;31(2):395–402.
pubmed: 21378317
Pandey KN. Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function. Physiol Genom. 2018;50(11):913–28.
Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL Jr. Biology of the natriuretic peptides. Am J Cardiol. 2008;101(3A):3–8.
pubmed: 18243856
Nakagawa Y, Nishikimi T, Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides. 2019;111:18–25.
pubmed: 29859763
Moyes AJ, Hobbs AJ. C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci. 2019;20(9):2281.
pmcid: 6539462
Schweitz H, Vigne P, Moinier D, Frelin C, Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 1992;267(20):13928–32.
pubmed: 1352773
Lisy O, Jougasaki M, Heublein DM, Schirger JA, Chen HH, Wennberg PW, Burnett JC. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int. 1999;56(2):502–8.
pubmed: 10432389
de Bold AJ, Bruneau BG, Kuroskide Bold ML. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 1996;31(1):7–18.
pubmed: 8849584
Rubattu S, Stanzione R, Cotugno M, Bianchi F, Marchitti S, Forte M. Epigenetic control of natriuretic peptides: implications for health and disease. Cell Mol Life Sci. 2020;77(24):5121–30.
pubmed: 32556416
Rubattu S, Calvieri C, Pagliaro B, Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013;31(6):1061–72.
pubmed: 23524910
Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57–77.
Špiranec Spes K, Chen W, Krebes L, Völker K, Abeßer M, Eder Negrin P, Cellini A, Nickel A, Nikolaev VO, Hofmann F, Schuh K, Schweda F, Kuhn M. Heart-microcirculation connection: effects of ANP (atrial natriuretic peptide) on pericytes participate in the acute and chronic regulation of arterial blood pressure. Hypertension. 2020;76(5):1637–48.
pubmed: 32951468
Forte M, Madonna M, Schiavon S, Valenti V, Versaci F, Zoccai GB, Frati G, Sciarretta S. Cardiovascular pleiotropic effects of natriuretic peptides. Int J Mol Sci. 2019;20(16):3874.
pmcid: 6719167
John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–81.
pubmed: 7839143
Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301–7.
pubmed: 2144261
Lopez MJ, Wong SK, Kishimoto I, Dubois S, Mach V, Friesen J, Garbers DL, Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378(6552):65–8.
pubmed: 7477288
Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 2000;97(8):4239–44.
pubmed: 10737768
pmcid: 18212
Fujii T, Hirota K, Yasoda A, Takizawa A, Morozumi N, Nakamura R, Yotsumoto T, Kondo E, Yamashita Y, Sakane Y, Kanai Y, Ueda Y, Yamauchi I, Yamanaka S, Nakao K, Kuwahara K, Jindo T, Furuya M, Mashimo T, Inagaki N, Serikawa T, Nakao K. Rats deficient C-type natriuretic peptide suffer from impaired skeletal growth without early death. PLoS ONE. 2018;13(3):e0194812.
pubmed: 29566041
pmcid: 5864047
Rubattu S, Evangelista A, Barbato D, Barba G, Stanzione R, Iacone R, Volpe M, Strazzullo P. Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans. J Hum Hypertens. 2007;21(10):822–4.
pubmed: 17525707
Cannone V, Cabassi A, Volpi R, Burnett JC Jr. Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease. Int J Mol Sci. 2019;20(13):3265.
pmcid: 6651335
Volpe M, Rubattu S, Burnett J Jr. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J. 2014;35(7):419–25.
pubmed: 24227810
Macheret F, Heublein D, Costello-Boerrigter LC, Boerrigter G, McKie P, Bellavia D, Mangiafico S, Ikeda Y, Bailey K, Scott CG, Sandberg S, Chen HH, Malatino L, Redfield MM, Rodeheffer R, Burnett J Jr, Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012;60(16):1558–65.
pubmed: 23058313
pmcid: 4041520
Rubattu S, Bigatti G, Evangelista A, Lanzani C, Stanzione R, Zagato L, Manunta P, Marchitti S, Venturelli V, Bianchi G, Volpe M, Stella P. Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol. 2006;48(3):499–505.
pubmed: 16875975
Chen C, Zhao Z, Xu J, Cao X, Guo S, Li J, Wang H, Hou S. Prokaryotic expression, purification and identification of recombinant human atrial natriuretic peptide. Sheng Wu Gong Cheng Xue Bao. 2016;32(9):1273–85.
pubmed: 29022328
Lin KF, Chao J, Chao L. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. Hypertension. 1995;26(6 Pt 1):847–53.
pubmed: 7490138
Lin KF, Chao J, Chao L. Atrial natriuretic peptide gene delivery reduces stroke-induced mortality rate in Dahl salt-sensitive rats. Hypertension. 1999;33(1 Pt 2):219–24.
pubmed: 9931108
Schillinger KJ, Tsai SY, Taffet GE, Reddy AK, Marian AJ, Entman ML, Oka K, Chan L, O’Malley BW. Regulatable atrial natriuretic peptide gene therapy for hypertension. Proc Natl Acad Sci USA. 2005;102(39):13789–94.
pubmed: 16162668
pmcid: 1236585
da Silva GJJ, Altara R, Booz GW, Cataliotti A. Atrial natriuretic peptide31–67: a novel therapeutic factor for cardiovascular diseases. Front Physiol. 2021;12:691407.
pubmed: 34305645
pmcid: 8297502
Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G, Schocken DD. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation. 1994 Sep;90(3):1129–40.
pubmed: 8087923
Kangawa K, Tawaragi Y, Oikawa S, Mizuno A, Sakuragawa Y, Nakazato H, Fukuda A, Minamino N, Matsuo H. Identification of rat gamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature. 1984;312(5990):152–5.
pubmed: 6239103
Nishi K, Sato Y, Miyamoto T, Toma M, Taniguchi R, Fukuhara R, Saijo S, Fujiwara H, Takatsu Y. Intermittent infusions of carperitide or inotoropes in out-patients with advanced heart failure. J Cardiol. 2012;59(3):366–73.
pubmed: 22365946
Sato N, Kajimoto K, Asai K, Mizuno M, Minami Y, Nagashima M, Murai K, Muanakata R, Yumino D, Meguro T, Kawana M, Nejima J, Satoh T, Mizuno K, Tanaka K, Kasanuki H, Takano T; ATTEND Investigators. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J. 2010;159(6):949–955.e1.
Hattori H, Minami Y, Mizuno M, Yumino D, Hoshi H, Arashi H, Nuki T, Sashida Y, Higashitani M, Serizawa N, Yamada N, Yamaguchi J, Mori F, Shiga T, Hagiwara N. Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes. Heart Vessels. 2013;28(3):345–51.
pubmed: 22526380
Mitrovic V, Forssmann WG, Schnitker J, Felix SB. Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2018 Dec;5(6):1023–34.
pubmed: 30246939
pmcid: 6300812
Anker SD, Ponikowski P, Mitrovic V, Peacock WF, Filippatos G. Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015;36(12):715–23.
pubmed: 25670819
pmcid: 4368857
Meems LMG, Burnett JC Jr. Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci. 2016;1(7):557–67.
pubmed: 28497128
pmcid: 5423722
McKie PM, Ichiki T, Burnett JC Jr. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012;14(1):62–9.
pubmed: 22135207
McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T, Burnett JC Jr. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010;56(6):1152–9.
pubmed: 20975033
Chen H, Wan SH, Iyer SR, Cannone V, Sangaralinghham J, Nuetel J, Burnett JC Jr. A first in human study of MANP: a novel atrial natriuretic peptide analogue in human hypertension. Hypertension 2021 (in press).
Chen BY, Chen JK, Zhu MZ, Zhang DL, Sun JS, Pei JM, Feng HS, Zhu XX, Jin J, Yu J. AC-NP: a novel chimeric peptide with natriuretic and vasorelaxing actions. PLoS ONE. 2011;6(5):e20477.
pubmed: 21647224
pmcid: 3101257
Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008;52(1):60–8.
pubmed: 18582636
pmcid: 2575424
Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl. 1999;17(1):S37-43.
pubmed: 10340842
Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607–13.
pubmed: 1321186
Kentsch M, Otter W, Drummer C, Nötges A, Gerzer R, Müller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51(3–4):269–72.
pubmed: 9010697
Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–11.
pubmed: 14751650
Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.
pubmed: 20236700
Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, Pal P, Yang F, Hirschhorn E, Prescott MF, Hinder M, Langenickel TH. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69(1):32–41.
pubmed: 27849566
Ibrahim NE, McCarthy CP, Shrestha S, Gaggin HK, Mukai R, Szymonifka J, Apple FS, Burnett JC Jr, Iyer S, Januzzi JL Jr. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73(11):1273–84.
pubmed: 30898202
Nougué H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F, Launay JM, Cohen-Solal A, Vodovar N, Logeart D. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598–605.
pubmed: 30520545
Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(13):2824.
pubmed: 34206864
pmcid: 8268164
Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, Sarzani R. Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287–97.
pubmed: 31147823
pmcid: 6853858
Spannella F, Giulietti F, Filipponi A, Sarzani R. Effect of sacubitril/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7:3487–96.
pmcid: 7754726
Rubattu S, Cotugno M, Forte M, Stanzione R, Bianchi F, Madonna M, Marchitti S, Volpe M. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat. J Hypertens. 2018;36(9):1902–14.
pubmed: 29916993
Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, Schiffrin EL. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. J Hypertens. 2008;26(2):322–33.
pubmed: 18192847
Volpe M, Gallo G. Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike? Eur Heart J. 2021;42(36):3753–5.
pubmed: 34392358
Volpe M, Tocci G, Battistoni A, Rubattu S. Angiotensin II receptor blocker neprilysin inhibitor (ARNI): new avenues in cardiovascular therapy. High Blood Press Cardiovasc Prev. 2015;22(3):241–6.
pubmed: 26100410
Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. J Hypertens. 2002;20(4):707–14.
pubmed: 11910307
Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P, Provost D, Hoffmann K, Fischer Y, Hocher B. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension. 2011;57(4):755–63.
pubmed: 21339476
Mulder P, Barbier S, Monteil C, Jeng AY, Henry JP, Renet S, Thuillez C. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure. J Cardiovasc Pharmacol. 2004;43(4):489–94.
pubmed: 15085059